...
首页> 外文期刊>Pharmaceuticals >Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99m Tc-Bone-Scintigraphy and [ 68 Ga]Ga-PSMA PET/CT
【24h】

Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99m Tc-Bone-Scintigraphy and [ 68 Ga]Ga-PSMA PET/CT

机译:前列腺癌患者骨转移的评估— 99m Tc骨闪烁显像和[68 Ga] Ga-PSMA PET / CT的比较

获取原文

摘要

Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by 99m Tc-MDP bone scan and 68 Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied.
机译:目的:骨闪烁显像是前列腺癌患者骨转移的参考标准。但是,在前列腺特异性膜抗原(PSMA)配体中使用的新型放射性示踪剂导致PET / CT作为诊断工具的重要性日益提高。我们研究的目的是调查骨扫描与PSMA-PET / CT在前列腺癌骨转移检测中的区别。方法:在平均21天内,通过99m Tc-MDP骨扫描和68 Ga-PSMA-PET / CT检查了30例前列腺癌骨转移患者。根据病变的数量并使用Exini Diagnostics的软件包ExiniBONE视觉分析骨扫描。目测分析PET / CT数据。比较了针对整个患者和不同区域的不同方法检测到的病变数量。此外,将结果与血清前列腺特异性抗原(PSA),碱性磷酸酶(ALP),骨碱性磷酸酶(bALP),促胃泌素释放肽(pGRP)和东部合作肿瘤小组(ECOG)的表现状态进行了比较。结果:在骨扫描中,视觉和半自动病变检测显示出相似的结果,每位患者平均检测到的骨病变为19.4和17.8。但是,在PSMA-PET / CT中,平均发现的病灶数量翻倍(40.0)。在胸部和骨盆中发现的差异最大,这可以用断层扫描成像的优势来解释。 Bland-Altman分析显示,发生大量骨转移的患者差异更大。结论:与视觉扫描相比,使用半自动分析与骨骼扫描无明显差异。骨扫描中发现的骨转移少于PSMA-PET / CT。但是,在我们的患者中,没有一个会导致临床后果。因此,对于接受PSMA-PET / CT的患者来说,如果应用了适当的PET / CT方案,则无需进行额外的骨扫描。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号